Navigation Links
Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference
Date:10/29/2008

y on cancer and various women's health indications. The company expects that the first microRNA diagnostic tests applying its technology will be launched by licensed clinical laboratories in the United States in 2008.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease and the expected timing of submission for approval and launch of diagnostic tests using our microRNA technology constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which is unproven and may never lead to marketable products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtai
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
2. Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative
3. Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"
4. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
5. Rosetta Genomics Reports Second Quarter 2008 Financial Results
6. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
7. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
8. Rosetta Genomics to Present at Collins Stewart Fourth Annual Growth Conference
9. Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer
10. Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
11. Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... Chief Executive Officer of Regulus, will present a company ... Annual Healthcare Conference on Wednesday, March 4, 2015 at ... the Boston Marriott Copley Place.  The ...
(Date:2/26/2015)... DuPont Executive Vice President James C. ... advancements and product launches across the Agriculture and Nutrition ... Lynch 2015 Global Agriculture Conference. "While ... the last two years, long-term demand for agricultural production ... last decade, when demand for corn and soybeans increased ...
(Date:2/26/2015)... On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a ... Genewiz Inc. in excess of $10 million. The jury ... secrets, and that it improperly hired one or more ... denying motions for judgment notwithstanding the verdict, a new ...
(Date:2/26/2015)... , Feb. 26, 2015 The healthcare landscape is ... arena, Frost & Sullivan will host its 20 th ... MindXchange , March 8 to 10, at the Hilton San ... This event is a platform for ... to discuss industry disruptions and how to succeed in an ...
Breaking Biology Technology:Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3
... Directors, EXTON, Pa., Nov. 5 Isolagen(TM), Inc. ... Meeting of,Stockholders, held today in Exton, Pennsylvania. Stockholders ... new Director.,Dr. Selzer has been a partner with the ... Selzer has been executive director,of the Hallowell-West Medical Center, ...
... Nov. 5 deCODE genetics,(Nasdaq: DCGN ) today ... 30, 2007. A conference call to discuss the,quarter,s results ... November 6, at 8:00am Eastern Standard Time/1pm GMT,(details below). ... 2007 was $24.2 million,compared to $23.6 million for the ...
... Will be Core Application for ... Wellness Programs, WASHINGTON, Nov. 5 Netsmart ... services for health and,human services organizations, today announced ... health software and provide related services to the,Detroit ...
Cached Biology Technology:Isolagen, Inc. Reports Results of Shareholders Annual Meeting 2Isolagen, Inc. Reports Results of Shareholders Annual Meeting 3deCODE genetics Announces Third Quarter 2007 Financial Results 2deCODE genetics Announces Third Quarter 2007 Financial Results 3deCODE genetics Announces Third Quarter 2007 Financial Results 4deCODE genetics Announces Third Quarter 2007 Financial Results 5deCODE genetics Announces Third Quarter 2007 Financial Results 6deCODE genetics Announces Third Quarter 2007 Financial Results 7deCODE genetics Announces Third Quarter 2007 Financial Results 8deCODE genetics Announces Third Quarter 2007 Financial Results 9Detroit Department of Health and Wellness Promotion Selects Netsmart Technologies Public Health Software 2
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... Issued by Small Cap IR. In 2011, Nilson Report,s annual ... merchants on the leading payment cards rose to $135.3 billion ... prepaid cards reached 6.54 billion.  Eight million credit card users ... 2012, and credit and debit card fraud resulted in $11.27 ...
(Date:1/22/2015)... N.C. , Jan. 22, 2015 Infinisource has launched ... of the G2 model. The G2 sets a higher standard ... iSolved human capital management solution. With plug-and-play installation, touch screen ... time clock provides a robust time collection solution for the ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Infinisource's NXG series sets new time clock standard 2
... Micro-organisms occurring naturally in coastal mudflats have an essential ... down petrochemical residues. Research by Dr Efe Aganbi and ... Society for General Microbiology,s meeting at Harrogate today (Monday ... degradation of the chemicals depending on whether or not ...
... 12-year-old Dutch boy bedridden for three years because ... join his friends on the soccer field thanks to ... , The investigators, led by Bjrn Knollmann, M.D., Ph.D., ... the clinically available drug flecainide prevents potentially lethal arrhythmias ...
... in Nature , researchers at Brandeis University and the ... time shed light on a crucial step in the complex ... in the human cell and frequently at which point genetic ... they were able to crystallize a very large complex of ...
Cached Biology News:Microbes in mud flats clean up oil spill chemicals 2Targeted drug therapy prevents exercise-induced arrhythmias 2Targeted drug therapy prevents exercise-induced arrhythmias 3A splice of life 2
mCD-1 10 transcription reactions...
Recombinant Rhesus Macaque IFN-alpha...
... g protein in 200 l SDS-PAGE Western blotting ... Abelson transformed macrophage cells, whole ... should be stored at -20C ... sample vial should be boiled ...
The epitope is specific for TASK and is not present in any other known proteins tested so far.,SPECIES REACTIVITIES: The epitope is also highly conserved between mouse and rat (17/18 residues iden...
Biology Products: